



# Novel indications for referral and care for simultaneous liver kidney transplant recipients

Erik L. Lum<sup>a</sup>, Suphamai Bunnapradist<sup>a</sup>, Alexander C. Wiseman<sup>b</sup>, Ahmet Gurakar<sup>c</sup>, Antony Ferrey<sup>d</sup>, Uttam Reddy<sup>d</sup> and Fawaz Al Ammary<sup>d</sup>

## Purpose of review

Kidney dysfunction is challenging in liver transplant candidates to determine whether it is reversible or not. This review focuses on the pertinent data on how to best approach liver transplant candidates with kidney dysfunction in the current era after implementing the simultaneous liver kidney (SLK) allocation policy and safety net.

## Recent findings

The implementation of the SLK policy inverted the steady rise in SLK transplants and improved the utilization of high-quality kidneys. Access to kidney transplantation following liver transplant alone (LTA) increased with favorable outcomes. Estimating GFR in liver transplant candidates remains challenging, and innovative methods are needed. SLK provided superior patient and graft survival compared to LTA only for patients with advanced CKD and dialysis at least 3 months. SLK can provide immunological protection against kidney rejection in highly sensitized candidates. Post-SLK transplant care is complex, with an increased risk of complications and hospitalization.

## Summary

The SLK policy improved kidney access and utilization. Transplant centers are encouraged, under the safety net, to reserve SLK for liver transplant candidates with advanced CKD or dialysis at least 3 months while allowing lower thresholds for highly sensitized patients. Herein, we propose a practical approach to liver transplant candidates with kidney dysfunction.

## Keywords

acute kidney injury, cirrhosis, chronic kidney disease, glomerular filtration rate, kidney transplant, liver transplant

## INTRODUCTION

Kidney dysfunction is a frequent complication in patients with decompensated cirrhosis, and it can be challenging to determine whether it is reversible or not. Acute kidney injury (AKI) is common in cirrhosis patients and is associated with increased mortality risk [1–3]. Kidney function has been an essential component for assigning priority to liver transplant candidates on the waiting list since implementing the model for end-stage liver disease (MELD) scoring system on February 27, 2002 [4–8]. The challenges in predicting kidney function reversibility and high prevalence of chronic kidney disease (CKD) following postliver transplant alone (LTA) had led the transplant community to a pattern of listing liver transplant candidates with kidney dysfunction for simultaneous liver kidney (SLK) [9,10]. The priority for multiorgan candidates resulted in allocating high-quality kidneys to SLK recipients who may recover their kidney function, where 50% of transplanted kidneys come from

donors with a kidney donor profile index (KDPI) of 35% or less [11]. This reduced the availability of such organs to patients on the kidney transplant waiting list who face increased mortality risk and

<sup>a</sup>Department of Medicine, University of California Los Angeles, Los Angeles, California, <sup>b</sup>Department of Medicine, Centura Health, Denver, Colorado, <sup>c</sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland and <sup>d</sup>Department of Medicine, University of California Irvine, Orange, California, USA

Correspondence to Fawaz Al Ammary, MD, PhD, Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, 333 City Blvd. West, City Tower, Suite 445, Orange, CA 92868-3298, USA. Tel: +1 714 385 4872; e-mail: fawaz.alammary@uci.edu

**Curr Opin Nephrol Hypertens** 2024, 33:354–360

DOI:10.1097/MNH.0000000000000970

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## KEY POINTS

- The SLK policy inverted the steady rise in SLK transplants and reduced center-level variability in SLK listing.
- The SLK policy improved access to kidney transplant following LTA without adversely affecting outcomes.
- Innovative methods are needed to estimate GFR in liver transplant candidates better.
- Under the safety net, transplant centers are encouraged to reserve SLK for liver transplant candidates with advanced CKD or dialysis at least 3 months while allowing lower thresholds for highly sensitized patients.
- The care of SLK recipients continues to remain complex, with a high burden of posttransplant complications. Programs are needed to optimize post SLK care.

shortage of living kidney donors [12,13]. Further, a substantial center-level variation existed in the SLK listing without specific eligibility criteria, which resulted in disparities in access to SLK [14,15].

The United Network for Organ Sharing (UNOS) implemented policies on August 10, 2017, to address unmet needs in adult SLK transplants [16,17]. These policies establish minimal eligibility criteria for SLK allocation and provide the ‘safety net’ to prioritize LTA recipients with kidney dysfunction in the first year after transplant to receive priority for kidney transplantation. This review discusses practical approaches to liver transplant candidates with kidney dysfunction in the current era.

## ACUTE KIDNEY INJURY VERSUS CHRONIC KIDNEY DISEASE IN LIVER TRANSPLANT CANDIDATES

Identifying reversible causes of kidney dysfunction is critical when deciding candidacy for SLK. History must document the onset and duration of AKI, prior history of reversible AKI, albuminuria, exposure to nephrotoxins, and risk factors for CKD to help differentiate AKI from CKD. The most common causes of AKI in decompensated cirrhosis are prerenal volume depletion, hepatorenal syndrome (HRS), and acute tubular necrosis (ATN) [18]. The clinical approach of kidney dysfunction in liver transplant candidates is similar to those without cirrhosis. However, specific liver-specific causes must be emphasized. Cirrhosis can result in portal hypertension and arterial vasodilatation in the splanchnic circulation, a condition resulting in kidney hypoperfusion and HRS [19]. Two clinical patterns of HRS exist (type 1 is more severe than type 2) and are

characterized by increased serum creatinine, bland urine, low urine sodium excretion, and no improvement in kidney function after volume expansion with intravenous albumin (1 g/kg/day) for at least 2 days and holding diuretics in the absence of shock [20]. HRS may respond to vasopressors in combination with albumin and timely liver transplantation [21,22]. Hepatitis B and C are common causes of liver disease that respond to therapy [23]. They may result in glomerulonephritis characterized by active urinary sediment with proteinuria and hematuria with evidence of glomerular inflammation on kidney biopsy. Nonalcoholic steatohepatitis (NASH) is an increasing cause of cirrhosis, and patients with NASH have a high rate of coexisting diabetes and hypertension, leading causes of CKD [23]. Patients with diabetic retinopathy are more likely to have diabetic nephropathy CKD.

Further, kidney imaging can establish CKD diagnosis when small-size kidneys or cortical thinning is present, as these are signs of irreversible kidney disease. While kidney biopsy is considered the gold standard for diagnosing the etiology of kidney disease, it is often deferred in liver transplant candidates due to the high risk of bleeding.

## ESTIMATION AND MEASUREMENT OF GLOMERULAR FILTRATION RATE IN LIVER TRANSPLANT CANDIDATES

An accurate kidney function assessment is essential to deciding liver and kidney allocation for liver transplant candidates with CKD or sustained AKI [24]. Serum creatinine-based estimated glomerular filtration rate (eGFR<sub>cr</sub>) is the most readily accessible and cost-effective endogenous filtration marker utilized in eGFR equations, where many were evaluated in cirrhosis patients [25–31]. In a study of 300 cirrhosis patients, measured GFR (mGFR), mean ( $\pm$ SD) 82 ( $\pm$ 29) ml/min/m<sup>2</sup> using iohexol clearance, was compared to creatinine-based equations (Modification of Diet in Renal Disease [MDRD] MDRD-4, MDRD-6, and Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI<sub>cr</sub>]). The MDRD-6 equation was superior to other equations in identifying cirrhosis patients with actual GFR less than 30 ml/min/1.73 m<sup>2</sup>, while it tended to underestimate renal function in a subgroup of patients with true GFR more than 30 ml/min/1.73 m<sup>2</sup> [32]. Similar findings were observed in another study, highlighting that MDRD-6 estimates correlate best with mGFR [33]. It is essential to recognize that serum creatinine based eGFR can overestimate GFR in patients with malnutrition, low muscle mass, and edema, which afflicts many cirrhotic patients. Cystatin C (cystC), on the other

hand, is less influenced by muscle mass or race. In a study of 202 cirrhosis patients, mGFR, mean 80 ( $\pm 31$ ) ml/min/m<sup>2</sup> using inulin clearance, was compared to cystC-based equations (CKD-EPIcystC, and CKD-EPIcr-cystC and Hoek) and creatinine-based equations (CKD-EPIcr, MDRD-4, MDRD-6). CystC-based equations performed better and had less bias, while creatinine-based equations overestimated mGFR [34]. However, the accuracy of cystC-based equations is limited at low eGFR [35]. It is also essential to understand that diabetes, obesity, smoking, inflammation/higher serum C-reactive protein and white blood cell count are associated with higher serum cystC. Moreover, measured creatinine clearance from timed urine collections overestimates actual GFR in cirrhosis patients, presumed due to increased tubular secretion of creatinine [36].

No single equation stands out for estimating GFR in cirrhosis patients [37]. While a more accurate eGFR equation is to be established in liver transplant candidates, in our view, CKD-EPIcystC can be used when eGFR is more than 30 ml/min/m<sup>2</sup> and MDRD-6 can be used when eGFR 30 ml/min/m<sup>2</sup> or less, acknowledging that mGFR is limited by availability,

cost, and technical requirements, especially in acute inpatient consult settings.

### SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY GOALS

The main goals of the SLK allocation policy by establishing minimal eligibility criteria were to reduce the number of unnecessarily allocated kidneys to liver candidates, and as such increase the number of kidney candidates transplanted; and to improve equity in access to transplants whether to a single organ or multiorgan candidate, including the pediatric access to high-quality kidneys. The SLK policy defines specific GFR values and duration of kidney disease for CKD and AKI eligibility criteria to help standardize SLK allocation to adult liver transplant candidates with kidney dysfunction (Table 1) [17].

The safety net policy was designed to avoid unintended consequences of the SLK policy for LTA recipients who may experience significant kidney dysfunction in the first-year post LTA. Safety net prioritizes LTA recipients on the kidney waiting list if they are on dialysis or have GFR 20 ml/min or less during the period of 60–365 days following their LTA.

**Table 1.** Medical eligibility criteria for liver-kidney allocation to adult liver transplant candidates<sup>a</sup> [17]

SLK allocation policy	
If the candidate's transplant nephrologist confirms a diagnosis of:	Then the transplant program must document in the candidate's medical record:
Chronic kidney disease (CKD) with GFR $\leq 60$ ml/min for $>90$ days	At least one of the following: 1. ESRD on chronic dialysis 2. GFR is $\leq 30$ ml/min at the time of registration or on a date after registration on the kidney waiting list.
Sustained acute kidney injury (AKI)	At least one of the following: 1. Dialysis for 6 consecutive weeks, at least once weekly. 2. GFR $\leq 25$ ml/min for 6 consecutive weeks, at least once weekly. 3. Combination of #1 and #2 for 6 consecutive weeks.
Metabolic disease	An additional diagnosis of at least one of the following: 1. Hyperoxaluria 2. Atypical hemolytic uremic syndrome (HUS) from mutations in factor H or factor I 3. Familial nonneuropathic systemic amyloid 4. Methylmalonic aciduria.
Liver Transplant Alone (LTA) and Safety Net <sup>b</sup>	
The candidate is registered on the kidney waiting list prior to the first anniversary of the candidate's most recent liver transplant date	At least one of the following in the period between 60 and 365 days post LTA: 1. Dialysis 2. GFR $\leq 20$ ml/min


<sup>a</sup>GFR can be measured or estimated. Consider the MDRD-6 equation for eGFR  $\leq 30$  ml/min and CKD-EPI Cystatin C for eGFR  $>30$  ml/min.

<sup>b</sup>Safety net gives priority to LTA recipients on the kidney waiting list. When the transplant program reports that the candidate meets the criteria for the safety net, the candidate will remain at this classification for 30 days from the date of the qualifying test or treatment. If the transplant program reports additional qualifying tests or treatments, then the candidate will remain at this classification for 30 days from the most recent date of the test or treatment. If the transplant program reports that the candidate meets the criteria for 90 consecutive days, the candidate will remain at this classification until the candidate is removed from the kidney waiting list.

## SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY IMPACT

The annual number of SLK transplants steadily rose and nearly doubled from 388 in 2010 to 739 in 2017. However, since the implementation of the SLK policy, the number of SLK transplants has plateaued in the 700s range yearly (Fig. 1) [38]. Early assessments post SLK policy indicate that it has achieved its goals [39]. Several studies demonstrated improved kidney access and utilization. SLK transplants as a proportion of all liver transplants decreased from 10.2% prepolicy to 9% post policy [40]. A study demonstrated reduced center-level and regional variability in SLK listing based on patient kidney function, as well as increased access to deceased donor kidney transplantation for LTA recipients with ESRD (defined as dialysis requirement at listing or transplant or eGFR <25 ml/min) and without difference in patient survival rates between SLK and LTA among patients with ESRD [41].

Prepolicy, 37% of SLK recipients had no dialysis and 22% had less than 2 months of dialysis, and of those who had no pretransplant dialysis, 40% had serum creatinine less than 2.5 mg/dl at the time of SLK transplants [11]. Post policy, 99% of SLK were listed for CKD criteria and 50% were on dialysis [42]. A study examined LTA patients with kidney dysfunction at listing (eGFR <30 ml/min or dialysis requirement) pre and post policy and found an increased listing for LTA for patients with kidney dysfunction, indicating a change in practice pattern, which resulted in a reduction in SLK listing. Significantly, under the safety net, the probability of kidney transplantation after LTA within 6 months of LTA increased from 26.7% prepolicy to 53% post policy, supporting the improved access to kidney transplantation following LTA while patient



**FIGURE 1.** Annual number of SLK recipients in the United States from 2010 to 2022.


survival remained unchanged [43]. In parallel, another study showed that the median waiting time for kidney transplantation after LTA was reduced from 2827 days prepolicy to 324 days post policy [44\*].

## SIMULTANEOUS LIVER KIDNEY VERSUS LIVER TRANSPLANT ALONE AND SAFETY NET FOR LIVER TRANSPLANT CANDIDATES

Reversibility of kidney function is a critical issue when determining SLK candidacy. It is essential to understand that the SLK policy provides minimal eligibility criteria and that eligibility does not mean candidacy. Additionally, all LTA recipients with kidney dysfunction who meet the safety net criteria are candidates to receive priority on the kidney waiting list if they are registered in the first-year post LTA. Nonetheless, SLK candidacy should be concluded after a careful evaluation by a transplant nephrologist, weighing the benefits and risks of SLK versus LTA and safety net. We propose a clinical approach to adult liver transplant candidates with kidney dysfunction in the current era (Fig. 2). A study found the probability of developing early-onset ESRD during the first 6 months post LTA was less than 5% [45]. Another study showed the risk of ESRD post LTA by 1 year was higher (26%) in patients with sustained eGFR less than 30 ml/min for the 90 days before LTA [46]. Further, a study evaluated the development of CKD following SLK using data from the U.S. multicenter SLK consortium. Of 570 SLK recipients, 10, 12, and 16% recipients developed CKD stage 4/5 by 1-year, 3-year, and 5-year post SLK, demonstrating the burden of kidney disease even following SLK [47]. In this study, delayed graft function (DGF) was associated with lower eGFR post SLK. Since DGF is associated with an increased risk for CKD following SLK, delaying kidney transplantation until after LTA recipients are clinically stable may lower the risk of DGF and 90 days mortality post SLK [48,49].

An area of controversy exists regarding the CKD eligibility criteria under the SLK policy. Liver transplant candidates with CKD, defined as an eGFR 60 ml/min or less for at least 3 months, can be listed for SLK once an eGFR reaches 30 ml/min or less. First, using a purely eGFR cutoff of 60 ml/min may result in CKD overdiagnosis in patients with end-stage liver disease without albuminuria or kidney damage, as these patients typically have volume overload with ascites and edema and are on dual diuretics. Second, most SLK recipients are older patients (in 2022, 27% were  $\geq 65$  years old, 47% were 50–65 years old, and 26% <50 years old) [38]. The





**FIGURE 2.** Approach to adult liver transplant candidates with kidney dysfunction. <sup>a</sup>CKD 3A (GFR 45–59 ml/min) patients without kidney damage (albuminuria, small-size kidneys, or cortical thinning) and not highly sensitized. In CKD 3A patients with kidney damage, follow CKD 3B next step.

CKD criteria do not weigh for patient age, recognizing that aged patients with an eGFR between 45 and 59 ml/min may not have true CKD without kidney damage [50,51]. Further, patients with AKI on CKD represent a broad spectrum of underlying causes of kidney dysfunction that may reverse and yet may inappropriately gain access to SLK. A study found that patients with AKI but normal kidney ultrasound findings had significant recovery of kidney function compared to patients with AKI with small kidneys (<9 cm in both kidneys). Of LTA recipients with documented CKD based on eGFR, 79% with normal kidney sizes had kidney function recovery compared to only 7.5% in those with small kidneys [52]. Therefore, SLK listing may be inappropriate for liver transplant candidates based on CKD stage 3A in the absence of kidney damage (albuminuria, small-size kidneys, or cortical thinning).

Multiple studies demonstrated the survival benefits of SLK only for those with advanced CKD. In a study of 5446 LTA or SLK adult recipients who potentially qualified for SLK, findings showed SLK was associated with a 1-year mortality benefit over LTA; however, this benefit was limited to SLK recipients with ESRD (defined as dialysis for ≥3 months), not for other kidney dysfunction criteria for SLK listing [53<sup>\*\*\*</sup>]. Another study found SLK provided higher patient survival compared with LTA in patients with kidney failure (defined as pretransplant dialysis ≥2 months or serum creatinine > 2.5 mg/dl) [11]. Similar findings were published on patients listed for SLK but received LTA;

maintenance dialysis for more than 3 months and age more than 60 years were associated with worse outcomes following LTA [54]. Moreover, in a matched-control analysis of 19 137 LTA and 1032 SLK recipients, SLK provided superior patient and graft survival compared to LTA only for patients on dialysis at least 3 months [55]. These studies suggest reserving SLK primarily to patients experiencing significant CKD only or dialysis at least 3 months.

While the literature appears to support LTA over SLK, except in cases of advanced kidney disease, the highly sensitized candidates are a group of patients for whom the safety net strategy may not be ideal. HLA antibodies and sensitization play a critical role in kidney transplantation outcomes; however, their role is much more limited in liver transplantation. Several studies demonstrate that SLK provides immunological protection against kidney rejection and preformed donor-specific antibodies, even in a positive crossmatch, which may be particularly important in highly sensitized candidates [56–58]. In our view, these patients need lower thresholds to receive SLK, given the difficulty in finding matched kidneys post LTA and the increased risk of kidney transplantation rejection.

## POST SIMULTANEOUS LIVER KIDNEY CARE

The care of post SLK recipients is complex and requires a multidisciplinary approach. While overall

survival remains excellent, recent studies highlight the significant early posttransplant burden for SLK recipients, including long lengths of stay and recurrent hospitalization. SLK length of stay (LOS) was examined in a study using data from the U.S.-multi-center SLK consortium; 71% of SLK recipients were hospitalized at the time of SLK (median pretransplant LOS was 10 days), and the median LOS for SLK transplants was 19 days, with increased LOS associated with higher mortality [59]. Female sex, black race, advanced age, ICU admission at time of SLK, MELD score prior to transplant, need for pre-SLK dialysis, and kidney DGF were associated with increased LOS, and 36% were discharged to a subacute rehab facility. Another U.S. multicenter SLK consortium analysis highlighted the high resource burden of SLK recipients. Of SLK recipients, 68% required hospitalization within 6 months post SLK, and the majority occurred within the first 30 days [60]. The most common cause of hospitalization post SLK was infections (25%). Risk factors for hospitalization were age, race, hospitalization at SLK, diabetes mellitus, BMI, and discharge to subacute rehab after SLK. These studies highlight the post-transplant medical challenges for SLK recipients. Additional studies are needed to identify modifiable risk factors and optimize post SLK care.

## CONCLUSION

The SLK allocation policy and safety net introduction has inverted the steady rise in SLK transplants, reduced center-level variability in SLK listing, and improved access to kidney transplantation following LTA without adversely affecting outcomes. Under the safety net, transplant centers are encouraged to reserve SLK for liver transplant candidates with advanced CKD or dialysis at least 3 months while allowing lower thresholds for highly sensitized patients. Innovative tools are needed to estimate GFR in liver transplant candidates better and to maximize the safety net option for those with potential recovery of their kidney function.

## Acknowledgements

None.

## Financial support and sponsorship

This work was supported, in part, by the National Institute of Diabetes and Digestive and Kidney Diseases: K23DK129820 (awarded to Dr Al Ammary).

## Conflicts of interest

None.

## REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Angeli P, Ginès P, Wong F, *et al.* Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. *J Hepatol* 2015; 62:968–974.
2. Gonwa TA, McBride MA, Anderson K, *et al.* Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLT) in the US: where will MELD lead us? *Am J Transplant* 2006; 6:2651–2659.
3. Belcher JM, Garcia-Tsao G, Sanyal AJ, *et al.* Association of AKI with mortality and complications in hospitalized patients with cirrhosis. *Hepatology* 2013; 57:753–762.
4. Kamath PS, Wiesner RH, Malinchoc M, *et al.* A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; 33:464–470.
5. Biggins SW, Kim WR, Terrault NA, *et al.* Evidence-based incorporation of serum sodium concentration into MELD. *Gastroenterology* 2006; 130:1652–1660.
6. Sharma P, Schaubel DE, Guidinger MK, *et al.* Impact of MELD-based allocation on end-stage renal disease after liver transplantation. *Am J Transplant* 2011; 11:2372–2378.
7. Nagai S, Chau LC, Schilke RE, *et al.* Effects of allocating livers for transplantation based on model for end-stage liver disease-sodium scores on patient outcomes. *Gastroenterology* 2018; 155:1451–1462; e3.
8. Kim WR, Mannalithara A, Heimbach JK, *et al.* MELD 3.0: the model for end-stage liver disease updated for the modern era. *Gastroenterology* 2021; 161:1887–1895; e4.
9. Ojo AO, Held PJ, Port FK, *et al.* Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003; 349:931–940.
10. Sung RS, Wiseman AC. Simultaneous liver-kidney transplant: too many or just enough? *Adv Chronic Kidney Dis* 2015; 22:399–403.
11. Formica RN, Aeder M, Boyle G, *et al.* Simultaneous liver-kidney allocation policy: a proposal to optimize appropriate utilization of scarce resources. *Am J T* 2016; 16:758–766.
12. Al Ammary F, Bowring MG, Massie AB, *et al.* The changing landscape of live kidney donation in the United States from 2005 to 2017. *Am J Transplant* 2019; 19:2614–2621.
13. Al Ammary F, Yu Y, Ferzola A, *et al.* The first increase in live kidney donation in the United States in 15 years. *Am J Transplant* 2020; 20:3590–3598.
14. Nadim MK, Davis CL, Sung R, *et al.* Simultaneous liver-kidney transplantation: a survey of US transplant centers. *Am J Transplant* 2012; 12:3119–3127.
15. Luo X, Massie AB, Haugen CE, *et al.* Baseline and center-level variation in simultaneous liver-kidney listing in the United States. *Transplantation* 2018; 102:609–615.
16. Simultaneous liver-kidney allocation (SLK) policy changes now in effect. Implementation date: Aug 10, 2017. <https://unos.org/news/simultaneous-liver-kidney-allocation-slk-policy-changes-now-in-effect/>. [Accessed 10 August 2023].
17. Organ Procurement and Transplantation Network (OPTN) policies. Health Resources and Services Administration, U.S. Department of Health & Human Services. [https://optn.transplant.hrsa.gov/media/1200/optn\\_policies.pdf](https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf). [Accessed 28 September 2023].
18. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. *J Hepatol* 2010; 52:605–613.
19. Biggins SW, Angeli P, Garcia-Tsao G, *et al.* Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021; 74:1014–1048.
20. Nadim MK, Kellum JA, Davenport A, *et al.* Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2012; 16:R23.
21. Boyer TD, Sanyal AJ, Wong F, *et al.* Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome Type 1. *Gastroenterology* 2016; 150:1579–1589; e2.
22. Wong F, Pappas SC, Curry MP, *et al.* Terlipressin plus albumin for the treatment of Type 1 hepatorenal syndrome. *N Engl J Med* 2021; 384:818–828.
23. Younossi ZM, Koenig AB, Abdelatif D, *et al.* Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; 64:73–84.
24. Francoz C, Prie D, Abdelrazek W, *et al.* Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. *Liver Transpl* 2010; 16:1169–1177.
25. Levey AS, Bosch JP, Lewis JB, *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann Intern Med* 1999; 130:461–470.

26. Levey AS, Coresh J, Greene T, *et al*. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate using standardized serum creatinine values for estimating glomerular filtration rate. *Ann Intern Med* 2006; 145:247–254.
27. Levey AS, Stevens LA, Schmid CH, *et al*. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150:604–612.
28. Inker LA, Schmid CH, Tighiouart H, *et al*. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012; 367:20–29.
29. Mindikoglu AL, Dowling TC, Magder LS, *et al*. Estimation of glomerular filtration rate in patients with cirrhosis by using new and conventional filtration markers and dimethylarginines. *Clin Gastroenterol Hepatol* 2016; 14:624–632; e2.
30. Kalafateli M, Wickham F, Burniston M, *et al*. Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: the royal free hospital cirrhosis glomerular filtration rate. *Hepatology* 2017; 65:582–591.
31. Asrani SK, Jennings LW, Trotter JF, *et al*. A model for glomerular filtration rate assessment in liver disease (GRAIL) in the presence of renal dysfunction. *Hepatology* 2019; 69:1219–1230.
32. Francoz C, Nadim MK, Baron A, *et al*. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. *Hepatology* 2014; 59:1514–1521.
33. Gonwa TA, Jennings L, Mai ML, *et al*. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. *Liver Transpl* 2004; 10:301–309.
34. De Souza V, Hadj-Aissa A, Dolomanova O, *et al*. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. *Hepatology* 2014; 59:1522–1531.
35. Torre A, Aguirre-Valadez JM, Arreola-Guerra JM, *et al*. Creatinine versus cystatin C for estimating GFR in patients with liver cirrhosis. *Am J Kidney Dis* 2016; 67:342–344.
36. Proulx NL, Akbari A, Garg AX, *et al*. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. *Nephrol Dial Transplant* 2005; 20:1617–1622.
37. Singapura P, Ma TW, Sarmast N, *et al*. Estimating glomerular filtration rate in cirrhosis using creatinine-based and cystatin C-based equations: systematic review and meta-analysis. *Liver Transpl* 2021; 27:1538–1552.
38. Organ Procurement and Transplantation Network: National Data Reports. <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#>. [Accessed 20 October 2023].
39. Cannon RM, Goldberg DS, Eckhoff DE, *et al*. Early outcomes with the Liver-kidney Safety Net. *Transplantation* 2021; 105:1261–1272.
40. Altshuler PJ, Shah AP, Frank AM, *et al*. Simultaneous liver kidney allocation policy and the Safety Net: an early examination of utilization and outcomes in the United States. *Transplant Int* 2021; 34:1052–1064.
41. Samoylova ML, Wegermann K, Shaw BI, *et al*. The impact of the 2017 Kidney Allocation Policy Change on simultaneous liver-kidney utilization and outcomes. *Liver Transpl* 2021; 27:1106–1115.
42. Wilk AR, Booker SE, Stewart DE, *et al*. Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: a 2-year review of the OPTN's allocation policy. *Am J Transplant* 2021; 21:3593–3607.
43. Nagai S, Suzuki Y, Kitajima T, *et al*. Paradigm change in liver transplantation practice after the implementation of the Liver-Kidney Allocation Policy. *Liver Transpl* 2021; 27:1563–1576.
44. Homkraisas P, Ayoub WS, Martin P, Bunnapradist S. Kidney utilization and outcomes of liver transplant recipients who were listed for kidney after liver transplant after the implementation of safety net policy. *Clin Transplant* 2022; 36:e14522.
- This study showed the median waiting time to kidney transplantation for patients who were listed for kidney after LTA was reduced from 2887 days before the SLK policy to 324 days after the implementation for the policy.
45. Israni AK, Xiong H, Liu J, *et al*. Predicting end-stage renal disease after liver transplant. *Am J Transplant* 2013; 13:1782–1792.
46. Ruebner R, Goldberg D, Abt PL, *et al*. Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction. *Am J Transplant* 2012; 12:2958–2965.
47. Sharma P, Sui Z, Zhang M, Magee JC, *et al*. Renal outcomes after simultaneous liver-kidney transplantation: results from the US Multicenter Simultaneous Liver-Kidney Transplantation Consortium. *Liver Transpl* 2021; 27:1144–1153.
48. Lunsford KE, Bodzin AS, Markovic D, *et al*. Avoiding futility in simultaneous liver-kidney transplantation: analysis of 331 consecutive patients listed for dual organ replacement. *Ann Surg* 2017; 265:1016–1024.
49. Fong TL, Bunnapradist S, Jordan SC, *et al*. Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation. *Transplantation* 2003; 76:348–353.
50. Liu P, Quinn RR, Lam NN, *et al*. Accounting for age in the definition of chronic kidney disease. *JAMA Intern Med* 2021; 181:1359–1366.
51. Delanaye P, Jager KJ, Bokenkamp A, *et al*. CKD: a call for an age-adapted definition. *J Am Soc Nephrol* 2019; 30:1785–1805.
52. Kim SB, Chang JW, Shin JH, *et al*. Renal recovery after liver transplantation alone in patients with liver cirrhosis and severe chronic kidney disease with normal kidney size. *Transplant Proc* 2021; 53:1719–1725.
53. Cheng XS, McElroy LM, Sanoff SL, Kwong AJ. One size does not fit all: differential benefits of simultaneous liver-kidney transplantation by eligibility criteria. *Liver Transpl* 2023; 29:1208–1215.
- This study assessed 5446 adult liver transplant or SLK recipients in the United States between January 1, 2015, and December 31, 2018, and tested effect modification by the specific SLK eligibility criteria met (end-stage kidney disease [dialysis  $\geq 90$  days]), AKI, CKD, or unknown). The study primary outcome was 1-year mortality benefit of SLK over liver-alone transplantation, and found that only in patients with end-stage kidney disease was SLK associated with a survival benefit.
54. Pita A, Kaur N, Emamaullee J, *et al*. Outcomes of liver transplantation in patients on renal replacement therapy: considerations for simultaneous liver kidney transplantation versus safety net. *Transplant Direct* 2019; 5:e490.
55. Locke JE, Warren DS, Singer AL, *et al*. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. *Transplantation* 2008; 85:935–942.
56. Taner T, Heimbach JK, Rosen CB, *et al*. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. *Kidney Int* 2016; 89:909–917.
57. Das A, Taner T, Kim J, Emamaullee J. Crossmatch, donor-specific antibody testing, and immunosuppression in simultaneous liver and kidney transplantation: a review. *Transplantation* 2021; 105:e285–e291.
58. Simpson N, Cho YW, Cicciarelli JC, *et al*. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS Database. *Transplantation* 2006; 82:1298–1303.
59. Barman PM, Patel YA, Xie J, *et al*. Predictors of length of stay and mortality during simultaneous liver-kidney transplant index admission: results from the US-Multicenter SLKT Consortium. *Transplant Direct* 2022; 8:e1408.
60. Sharma P, Xie J, Wang L, *et al*. Burden of early hospitalization after simultaneous liver-kidney transplantation: results from the US Multicenter SLKT Consortium. *Liver Transpl* 2022; 28:1756–1765.